Screening to beginning at age 20 years**
Determine Patient Risk

0-1 Major ASCVD Risk Factor* w/ Pooled Cohorts Risk Score <7.5%
Follow Low Risk Patient Algorithm pg. 2

2 major ASCVD Risk Factors*
Follow Moderate Risk Patient Algorithm pg. 3

• DM I or II
• LDL ≥190 mg/dL
• LDL 70-189 mg/dL w/ pooled cohort risk score ≥7.5%
Follow High Risk Patient Algorithm pg. 4

• Clinical ASCVD
• DM I or II with ≥ 2 ASCVD Risk Factors*
Follow Very High Risk Patient Algorithm pg. 5

Clinical Atherosclerotic cardiovascular disease (ASCVD)
- Myocardial infarction or other Acute Coronary Syndrome
- Coronary or other revascularization procedure
- Transient ischemic attack
- Ischemic stroke
- Atherosclerotic peripheral arterial disease (includes ankle/brachial index <0.90)
- Documented atherosclerotic diseases such as:
  • Coronary atherosclerosis
  • Renal atherosclerosis
  • Aortic aneurysm secondary to atherosclerosis
  • Carotid plaque, ≥ 50%

**consider stopping screening at age 80 if clinically indicated

*ASCVD Risk Factors
- Smoking
- Hypertension
- Low HDL (<40 mg/dL)
- Family History of premature CHD (<55 years male relative; <65 years female relative)
- Age (>45 years male; >55 years female)

1 Primary target-Non-HDL (NHDL)
Secondary target-LDL

LGHealth
Lipid Guidelines

Created Lipid Taskforce
December 2014
**ASCVD Risk Factors**

- Smoking
- Hypertension
- Low HDL (<40 mg/dL)
- Family History of premature CHD (<55 years male relative; <65 years female relative)
- Age (>45 years male; >55 years female)

---

**Additional Diagnostic Testing**

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference</th>
<th>Consider Treatment</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsCRP</td>
<td>Jupiter</td>
<td>≥ 2.0 mg/dL</td>
<td>$</td>
</tr>
<tr>
<td>CT Ca Score</td>
<td>Mesa</td>
<td>≥ 300 Agastston Units or 75th percentile for age, sex, and ethnicity</td>
<td>$</td>
</tr>
</tbody>
</table>

**Primary target-NHDL**

**Secondary target-LDL**
**ASCVD Risk Factors**
- Smoking
- Hypertension
- Low HDL (<40 mg/dL)
- Family History of premature CHD (<55 years male relative; <65 years female relative)
- Age (>45 years male; >55 years female)

*Primary target-NHDL
Secondary target-LDL

**Additional Diagnostic Testing**

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference</th>
<th>Consider Treatment</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsCRP</td>
<td>Jupiter</td>
<td>≥ 2.0 mg/dL</td>
<td>$</td>
</tr>
<tr>
<td>CT Ca Score</td>
<td>Mesa</td>
<td>≥ 300 Agastston Units or 75th percentile for age, sex, and ethnicity</td>
<td>$</td>
</tr>
</tbody>
</table>

Cost Key:
- $  <$100
- $$  $101-500
- $$$  $501-1000
- $$$$  >$1000
High Risk Patient Algorithm

- DM I or II
- LDL ≥190 mg/dL
- LDL 70-189 w/ pooled cohort risk score ≥7.5%

Therapeutic Lifestyle Changes (TLC) AND moderate or high intensity statin for 8-12 weeks

Check lipid levels every year

Goals achieved Maintain Lipid Levels

NHDL <130 LDL <100

FIRST VISIT

NO

Intensify Statin or Add second drug

SECOND VISIT

NO

Add second drug if not already done

THIRD VISIT

Consider referral to Lipid Specialist

Statin Therapy

<table>
<thead>
<tr>
<th>Statin Therapy</th>
<th>Cost</th>
</tr>
</thead>
</table>
| Moderate
| Rosuvastatin 5-10mg | $ |
| Atorvastatin 10-20mg | $ |
| Pitavastatin 2-4mg | $$$ |
| Simvastatin 20-40mg | $ |
| Lovastatin 40mg | $ |
| Pravastatin 40-80mg | $ |
| Fluvastatin XL 80mg | $ |
| Fluvastatin 40 mg BID | $ |
| High
| Rosuvastatin 20-40mg | $$$ |
| Atorvastatin 40-80mg | $ |

Cost Key:
$ < $100
$$ $101-500

Primary target-NHDL
Secondary target-LDL
Clinical ASCVD
Myocardial infarction or other Acute Coronary Syndrome
Coronary or other revascularization procedure
Transient ischemic attack
Ischemic stroke
Atherosclerotic peripheral arterial disease (includes ankle/brachial index <0.90)
Documented atherosclerotic diseases such as:
- Coronary atherosclerosis
- Renal atherosclerosis
- Aortic aneurysm secondary to atherosclerosis
- Carotid plaque, ≥ 50%

ASCVD Risk Factors
Smoking
Hypertension
Low HDL (<40 mg/dL)
Family History of premature CHD (<55 years male relative; <65 years female relative)
Age (≥45 years male; ≥55 years female)

Therapeutic Lifestyle Changes (TLC) and high intensity statin * for 8-12 weeks

Goals achieved
Maintain Lipid Levels
NHDL <100
LDL <70

Check lipid levels yearly

Recurrent clinical events despite NHDL <100 LDL <70

Refers to Lipid Specialist for:
1) Additional drug therapy including novel drugs
2) Advanced lipid testing
3) Lipid apheresis if LDL ≥ 200 with CAD

Statin Therapy

<table>
<thead>
<tr>
<th>Statin Therapy</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin 5-10mg</td>
<td>$$$</td>
</tr>
<tr>
<td>Atorvastatin 10-20mg</td>
<td>$</td>
</tr>
<tr>
<td>Pitavastatin 2-4mg</td>
<td>$$$</td>
</tr>
<tr>
<td>Simvastatin 20-40mg</td>
<td>$</td>
</tr>
<tr>
<td>Lovastatin 40mg</td>
<td>$</td>
</tr>
<tr>
<td>Pravastatin 40-80mg</td>
<td>$</td>
</tr>
<tr>
<td>Fluvastatin XL 80mg</td>
<td>$</td>
</tr>
<tr>
<td>Fluvastatin 40 mg BID</td>
<td>$</td>
</tr>
<tr>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin 20-40mg</td>
<td>$$$</td>
</tr>
<tr>
<td>Atorvastatin 40-80mg</td>
<td>$</td>
</tr>
</tbody>
</table>

Cost Key:
$ <$100  $$ $101-500